Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
暂无分享,去创建一个
T. Mitsudomi | Kazutaka Nakashima | M. Kuwano | M. Ono | K. Azuma | S. Hattori | H. Aizawa | C. Yamamoto | M. Kage | Y. Basaki | A. Kawahara | Masaki Kashihara
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[3] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Loda,et al. Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.
[5] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[6] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[7] Y. Bang,et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. , 2006, Lung cancer.
[8] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Haber,et al. Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms , 2008, Clinical Cancer Research.
[10] Mayumi Ono,et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.
[11] M. Kuwano,et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.
[12] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Hai-sheng Zhou,et al. Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[14] J. Soh,et al. The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer , 2007, Clinical Cancer Research.
[15] F. Bray,et al. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising , 2005, International journal of cancer.
[16] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[17] Shih-Feng Tsai,et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.
[18] M. Kuwano,et al. Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs , 2006, Clinical Cancer Research.
[19] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[20] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[21] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[22] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.